Romanian Society of Pharmaceutical Sciences
 

« Back to Farmacia Journal 2/2019

HYDROXYSAFFLOR YELLOW A REVERSE CHEMOTHERAPY RESISTANCE VIA JNK AND P38 MAPK SIGNAL PATHWAY IN OVARIAN CANCER CELLS

CHENYU JIN 1, JIALE YING 2, WEIJI YANG 3, RUOJIA LIANG 4*

1.Department of Traditional Chinese Medicine, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310009, China
2.The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China
3.College of Life Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China
4.Department of Gynaecology, The First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310006, China

Download Full Article PDF

Cisplatin based combination chemotherapy has become a conventional treatment for ovarian cancer. However, the appearance of drug resistance during the ovarian cancer treatment is one of the main obstacles for improving the therapeutic perspective of ovarian cancer. The aim of this study was to confirm the hypothesis that Hydroxysafflor yellow A (HYSA) can reverse chemotherapy resistance in ovarian cancer cells. In vitro study on A2780/DDP ovarian cell line was used to monitor cell proliferation by cytotoxicity assay and real time cellular analysis associated with flow cytometry that intend to determine if HSYA enhance cisplatin sensitivity through apoptosis. In vivo experiments on mice was used to identify the HYSA effects on cisplatin sensitivity. The in vitro studies showed that MAPK signal pathways were suppressed in cisplatin resistant ovarian cells A2780/DDP. Also, HSYA enhanced cisplatin sensitivity in cisplatin resistant organisms, in vivo. Mechanistically, HYSA increase P-JNK and P-38 levels, but has no effect on P-ERK, indicating that HYSA enhanced cisplatin sensitivity via JNK and P38 MAPK signalling pathways.